Apalutamide and ADT elicited a 100% biochemical recurrence-free survival rate at 24 months in high-risk localized prostate cancer following radical prostatectomy.
Article highlights results from successful Phase 2a clinical trial for lead candidate, LP-10
Lipella expects to initiate Phase 2b clinical trial in LP-10 in early 2024
PITTSBURGH, Pa., Sept. 21,.
Lipella Pharmaceuticals (LIPO) Phase 2a Clinical Study Results Published in the Journal of Urology and Nephrology streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Many practices struggle with staff shortages, which affect billings, patient care, administrative tasks, and revenue issues. There are ways to prevent this.